Core Laboratories Inc. (NYSE:CLB) Stake Reduced by Boston Trust Walden Corp

Boston Trust Walden Corp trimmed its holdings in shares of Core Laboratories Inc. (NYSE:CLB - Free Report) by 17.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 600,833 shares of the oil and gas company's stock after selling 128,927 shares during the period. Boston Trust Walden Corp owned 1.28% of Core Laboratories worth $11,133,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Headlands Technologies LLC purchased a new stake in shares of Core Laboratories during the second quarter valued at approximately $36,000. nVerses Capital LLC acquired a new stake in Core Laboratories during the 3rd quarter valued at $48,000. GAMMA Investing LLC increased its stake in Core Laboratories by 23.9% during the 2nd quarter. GAMMA Investing LLC now owns 4,425 shares of the oil and gas company's stock worth $90,000 after buying an additional 855 shares during the period. Platinum Investment Management Ltd. lifted its holdings in Core Laboratories by 13.9% in the 1st quarter. Platinum Investment Management Ltd. now owns 6,351 shares of the oil and gas company's stock worth $108,000 after buying an additional 774 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its position in Core Laboratories by 11.9% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 5,636 shares of the oil and gas company's stock valued at $114,000 after buying an additional 600 shares during the last quarter. 97.81% of the stock is currently owned by institutional investors and hedge funds.

Core Laboratories Stock Performance

Shares of CLB traded up $0.49 during mid-day trading on Friday, hitting $19.43. The stock had a trading volume of 285,303 shares, compared to its average volume of 434,035. Core Laboratories Inc. has a fifty-two week low of $13.82 and a fifty-two week high of $25.13. The company has a quick ratio of 1.68, a current ratio of 2.39 and a debt-to-equity ratio of 0.60. The company has a market cap of $911.27 million, a PE ratio of 22.08, a PEG ratio of 1.08 and a beta of 2.36. The company's fifty day simple moving average is $18.53 and its two-hundred day simple moving average is $18.99.

Core Laboratories (NYSE:CLB - Get Free Report) last released its quarterly earnings data on Wednesday, October 23rd. The oil and gas company reported $0.25 EPS for the quarter, topping analysts' consensus estimates of $0.21 by $0.04. The firm had revenue of $134.40 million during the quarter, compared to the consensus estimate of $134.16 million. Core Laboratories had a net margin of 5.44% and a return on equity of 15.20%. The firm's revenue was up 7.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.22 earnings per share. On average, equities analysts expect that Core Laboratories Inc. will post 0.8 earnings per share for the current year.

Core Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 25th. Investors of record on Monday, November 4th will be given a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.21%. The ex-dividend date of this dividend is Monday, November 4th. Core Laboratories's dividend payout ratio is presently 4.55%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Piper Sandler cut their price target on Core Laboratories from $18.00 to $17.00 and set a "neutral" rating on the stock in a research note on Monday, July 15th. StockNews.com cut Core Laboratories from a "hold" rating to a "sell" rating in a research note on Tuesday, September 17th. Stifel Nicolaus raised their price target on shares of Core Laboratories from $18.00 to $22.00 and gave the stock a "hold" rating in a research report on Friday, July 26th. Finally, Bank of America cut their price target on shares of Core Laboratories from $16.00 to $15.00 and set an "underperform" rating on the stock in a report on Monday, July 15th. Two research analysts have rated the stock with a sell rating and two have issued a hold rating to the stock. According to data from MarketBeat, Core Laboratories currently has a consensus rating of "Hold" and a consensus price target of $18.00.

About Core Laboratories

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.